Cannabis-Based Medicines · GMP/GPP · Health Canada Licensed
CNPG and its Phant brand represent a comprehensive portfolio of cannabis-based medicines — manufactured to GMP/GPP standards and supplied through licensed medical channels in international markets.
18
Products
5
Markets
GMP
Health Canada
COA
Every Batch
Products
The range is organised into medicinal flower and extracts (including cartridges, oral oil, and bulk supply). Every batch carries a full Certificate of Analysis.
Flower
7 SKUs · View range →
Extracts
11 SKUs · View range →
GACP-certified inputs · Health Canada GMP/GPP manufacture · Independent laboratory release testing on every batch.
Standards
Every product begins with certified cultivators and ends with a batch-specific Certificate of Analysis. For production context see Supply chain or Regulatory information.
GMP
Canadian GMP / GPP
Manufactured, packaged, and released to Canadian GMP/GPP requirements.
GACP
Agricultural compliance
Input material from GACP-certified or CNPG-vetted Canadian cultivators.
COA
Batch testing
Cannabinoids, terpenes, microbiology, mycotoxins, heavy metals, residuals, and pesticides.
Sch.2
UK CBPM pathway
UK products released in line with MHRA guidance for unlicensed CBPMs.
Our Markets
Each market served through locally licensed distribution channels. Contact us to discuss your jurisdiction.
United Kingdom
Active
Flower · Cannabis Flower Extracts · Live Resin · Distillate · Oral Oil
Germany
Active
Cannabis Extract · Licensed distribution established
Czech Republic
Active
Cannabis Extract · Licensed distribution established
South Africa
Active
Bulk Live Resin · For licensed processors
Australia
Active
THCa · Bulk formats · For licensed processors
Contact
For prescriber documentation, supply enquiries, distribution partnerships, or new market discussions — get in touch with the CNPG team directly.
Product Enquiries
Product information, documentation, and clinical enquiries about specific Phant products.
Sales & Distribution
Distribution partnerships, wholesale, new market discussions, and bulk supply enquiries.
Regulatory note — Products distributed in the United Kingdom are classified and supplied as Cannabis-Based Products for Medicinal Use (CBPMs) under Schedule 2 of the UK Misuse of Drugs Regulations 2001, released in line with MHRA guidance for unlicensed CBPMs. Products in other markets are supplied in compliance with the applicable regulatory requirements of each jurisdiction. This website is intended for medical professionals, licensed distributors, and qualified procurement teams. Not for patient self-referral or recreational use. Version 1.0 · April 2026 · Review annually. Produced by CNPG / Phant.